<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lifecore Biomedical Inc. — News on 6ix</title>
<link>https://6ix.com/company/lifecore-biomedical-inc</link>
<description>Latest news and press releases for Lifecore Biomedical Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lifecore-biomedical-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683590ba78dffbe2df102286.webp</url>
<title>Lifecore Biomedical Inc.</title>
<link>https://6ix.com/company/lifecore-biomedical-inc</link>
</image>
<item>
<title>Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-report-financial-results-for-the-first-quarter-ended-march-31-2026-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-report-financial-results-for-the-first-quarter-ended-march-31-2026-on-may-6-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>Webcast Scheduled for Wednesday, May 6 at 8:00 a.m. EasternCHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, before the market opens. At 8:00 a.m. Eastern Time that day, members of Lifecore’s senior management team will host a</description>
</item>
<item>
<title>Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-participate-at-12th-annual-american-biomanufacturing-summit</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-participate-at-12th-annual-american-biomanufacturing-summit</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit. The conference will take place April 14 - 15, 2026, in San Francisco, CA. Details regarding Lifecore’s participation are as follows: 12th Annual American Biomanufacturing SummitDetails: Lifecore team</description>
</item>
<item>
<title>Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-two-new-agreements-with-existing-us-biopharmaceutical-customer</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-two-new-agreements-with-existing-us-biopharmaceutical-customer</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially</description>
</item>
<item>
<title>Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-commercial-site-transfer-agreement-with-leading-medical-aesthetics-company</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-commercial-site-transfer-agreement-with-leading-medical-aesthetics-company</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- --</description>
</item>
<item>
<title>Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-reports-financial-results-for-the-fourth-quarter-and-transition-period-ended-december-31-2025-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-reports-financial-results-for-the-fourth-quarter-and-transition-period-ended-december-31-2025-and-provides-corporate-update</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025</description>
</item>
<item>
<title>Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-participate-in-6th-annual-keybanc-capital-markets-healthcare-virtual-forum-8</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-participate-in-6th-annual-keybanc-capital-markets-healthcare-virtual-forum-8</guid>
<pubDate>Tue, 10 Mar 2026 20:05:00 GMT</pubDate>
<description>CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore’s participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat</description>
</item>
<item>
<title>Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-report-financial-results-for-the-fourth-quarter-and-transition-period-ended-december-31-2025-on-march-16-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-to-report-financial-results-for-the-fourth-quarter-and-transition-period-ended-december-31-2025-on-march-16-2026-4</guid>
<pubDate>Mon, 09 Mar 2026 20:05:00 GMT</pubDate>
<description>Webcast Scheduled for Monday, March 16 at 8:30 a.m. EasternCHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time that day, members of Lifecore’s senior ma</description>
</item>
<item>
<title>Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-new-agreement-with-indomo-to-support-innovative-drugdevice-combination-acne-treatment-91</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-new-agreement-with-indomo-to-support-innovative-drugdevice-combination-acne-treatment-91</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal</description>
</item>
<item>
<title>Lifecore Biomedical to Participate at DCAT Week 2026</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-dcat-week-120500897</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-dcat-week-120500897</guid>
<pubDate>Tue, 17 Feb 2026 12:05:00 GMT</pubDate>
<description>CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City. Details regarding Lifecore’s participation are as follows: DCAT Week 2026Details: Lifecore team will host customers and prospective partners to discuss development an</description>
</item>
<item>
<title>Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-announces-inducement-grants-under-214500817</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-announces-inducement-grants-under-214500817</guid>
<pubDate>Fri, 16 Jan 2026 21:45:00 GMT</pubDate>
<description>CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 sha</description>
</item>
<item>
<title>Lifecore Biomedical to be Added to Nasdaq Biotech Index</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-added-nasdaq-biotech-120000135</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-added-nasdaq-biotech-120000135</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December</description>
</item>
<item>
<title>Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-cdmo-master-120000285</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-cdmo-master-120000285</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large</description>
</item>
<item>
<title>Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer </title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-cdmo-master-services-agreement-with-new-large-multinational-pharmaceutical-customer</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-signs-cdmo-master-services-agreement-with-new-large-multinational-pharmaceutical-customer</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program</description>
</item>
<item>
<title>Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-44th-annual-120000836</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-44th-annual-120000836</guid>
<pubDate>Tue, 16 Dec 2025 12:00:00 GMT</pubDate>
<description>CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore managem</description>
</item>
<item>
<title>Lifecore Biomedical to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-upcoming-investor-210500227</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-upcoming-investor-210500227</guid>
<pubDate>Tue, 11 Nov 2025 21:05:00 GMT</pubDate>
<description>CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and L</description>
</item>
<item>
<title>Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-reports-financial-results-210500445</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-reports-financial-results-210500445</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>-- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“C</description>
</item>
<item>
<title>Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-report-financial-results-200500950</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-report-financial-results-200500950</guid>
<pubDate>Thu, 30 Oct 2025 20:05:00 GMT</pubDate>
<description>Webcast Scheduled for Thursday, November 6 at 4:30 p.m. EasternCHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast</description>
</item>
<item>
<title>Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-selected-commercial-manufacturing-110000584</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-selected-commercial-manufacturing-110000584</guid>
<pubDate>Wed, 29 Oct 2025 11:00:00 GMT</pubDate>
<description>Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organi</description>
</item>
<item>
<title>Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-polypeptide-announce-collaboration-intended-110000119</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-polypeptide-announce-collaboration-intended-110000119</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S. The colla</description>
</item>
<item>
<title>Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events</title>
<link>https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-upcoming-industry-110000530</link>
<guid isPermaLink="true">https://6ix.com/company/lifecore-biomedical-inc/news/lifecore-biomedical-participate-upcoming-industry-110000530</guid>
<pubDate>Mon, 13 Oct 2025 11:00:00 GMT</pubDate>
<description>CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows: 15th Annual Partnership Opportunities in Drug Development (PODD)Conference Dates/Location: October 27-28, 2025, in Boston, MADetails: Ryan Swanson, Ph.D., Lifecor</description>
</item>
</channel>
</rss>